Selective drug release from internalized conjugates of biologically active compounds
US12036286B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 17, 2022 |
| Grant date | Jul 16, 2024 |
| Priority date | — |
| Expiry date | Mar 17, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to conjugates of biologically active compounds, wherein such a conjugate is comprised of a sequence of amino acids containing a tripeptide that confers selective cleavage by tumor tissue homogenate for release of free drug and/or improves biodistribution into the tumor tissue in comparison to normal tissue homogenate from the same species, wherein the normal tissue is the site of an adverse event associated with administration to a human subject in need thereof of a therapeutically effective amount of a comparator conjugate whose amino acid sequence is a dipeptide known to be selectively cleavable by Cathepsin B.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.